A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Radiation Therapy Treatment Planning

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00026936

Enrollment

140

Registered

2001-11-15

Start date

1999-05-31

Completion date

2005-01-31

Last updated

2008-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasm

Keywords

External Beam Radiotherapy, TCP, DVH, NTCP, 3-D Programming

Brief summary

The utility of PEREGRINE Monte Carlo calculations for radiation treatment planning in a clinical setting will be assessed by comparing results with other fully three-dimensional programs. ROB will investigate PEREGRINE for clinical use at NCI in collaboration with Lawrence Livermore National Laboratory (LLNL).

Detailed description

Interventions

PROCEDURERadiotherapy

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Patients with documented malignancy requiring standard radiotherapy OR patients with a benign condition for whom radiotherapy is indicated.

Exclusion criteria

Documented connective tissue disease or Ataxia Telangiectasia. Cognitively impaired patients who cannot give informed consent. Other medical conditions deemed by the PI to make the patient ineligible. Patients requiring emergent radiotherapy. Patients who are not able to undergo a CT scan.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026